Phaseline

Companies › Kylonova (Xiamen) Biopharma

Kylonova (Xiamen) Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine, Other; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Kylo-11
Lipoprotein(a) lowering agent
–Phase 2Lipoprotein DisorderAug 2028
Kylo-12–Phase 1Hypertriglyceridemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06783881Kylo-12Phase 1HypertriglyceridemiaMetabolic and endocrineDec 2025
NCT07327840Kylo-11Phase 2Lipoprotein DisorderOtherAug 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

OPKO Health CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Lallemand Health Solutions BrightGene Bio-Medical Technology Sirnaomics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.